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Introduction
The pro-inflammatory peptide bradykinin is a powerful modulator of vascular permeability. It is a key disease mediator in hereditary angioedema (HAE) [1] and implicated in sepsis [2] , anaphylactic shock [3] and rheumatoid arthritis [4] . Bradykinin is produced by the plasma contact system, in which the enzyme factor XII (FXII) plays an initiating role. FXII belongs to the family of trypsinlike serine proteases, which are produced in an inactive form (zymogen). A cleavage event near their catalytic domain causes a conformational change, which mediates activation [5, 6] . When plasma contacts anionic surface materials, FXII is activated through successive cleavage events by plasma kallikrein (PKa). It is generally assumed that FXII (an 80 kDa single chain protein) is first cleaved after position R353 to yield activated FXII (aFXIIa; an 80 kDa disulfide-linked two-chain protein). This molecule can act as a clotting factor. Subsequent cleavages, in particular after R334, truncate the molecule (bFXIIa; a 28 kDa disulfide-linked two-chain protein). This eliminates the domains that are essential for binding to prothrombotic surfaces, resulting in a selective activator of plasma prekallikrein (PK) that lacks the capacity to act as a clotting factor [7] .
During binding to activating surfaces, the FXII molecule changes conformation, which exposes the R353 cleavage site that is essential for zymogen activation [8] . This conformational change can be recapitulated by the binding of specific monoclonal antibodies that recognize the FXII fibronectin type II or kringle domain [9, 10] . This suggests that the activating cleavage site is shielded from PKa when FXII is in a globular form, restricting FXII activation to the activating surface. Similar mechanisms have already been described for prothrombin and plasminogen [11] [12] [13] .
We recently identified that mutations in FXII that cause HAE (FXII-HAE) introduce additional cleavage sites into the FXII molecule. When plasmin cleaves at these sites, uncontrolled FXII activation occurs and bradykinin production follows [14] . We proposed that this represents a two-stage activation mechanism: first, FXII is cleaved, which truncates the molecule and exposes the activating cleavage site. Subsequently, it is activated through cleavage after R353. We hypothesized that this leads to excessive FXII activation in solution, without a surface as a prerequisite [15] .
In this study, we hypothesized that the disease mechanism of FXII-HAE reflects a physiological pathway for FXII activation in solution. We here report that the proline-rich region of FXII contains several enzyme cleavage sites for a variety of enzymes, including neutrophil elastase and monocyte-expressed cathepsin K, two enzymes that are not classically linked to contact system activation. Cleavage by these enzymes removes a large shielding sequence from the FXII molecule and primes it for activating cleavage by PKa. Based on these findings, we propose a general two-step model for FXII activation by cell-derived enzymes, which helps us to understand how bradykinin production may occur in inflammatory conditions.
Methods

Reagents
A list of reagents is provided in Data S1.
Protein expression and purification
Factor XII mutagenesis and production were performed as previously described [14] . Briefly, mutations R334A and R353A were generated via site-directed mutagenesis using Pfu turbo (see Table S1 for primer sequences). FXII constructs were ligated into the pSM2 eukaryotic expression vector via the HindIII and EcoRI digestion sites. pSM2 contains an N-terminal murine IgK secretion signal followed by two strep-tags for purification. FXII constructs were transfected into HEK293T cells with Lipofectamine 2000, after which transfected cells were selected by resistance to 5 lg mL À1 blasticidin. After Protein concentrations were determined by absorption spectroscopy at OD 280nm . Absorption coefficients of the FXII mutants were determined based on their mature amino acid sequences using ProtParam [16] . Purity and degradation were assessed via 4-12% Bis Tris-PAGE gel and coomassie blue staining.
Plasminogen purification and activation
Plasminogen was purified from human plasma as previously described [14] . Plasmin was freshly prepared for functional experiments by preactivation of plasminogen with 10 U mL À1 streptokinase in 10 mmol L À1 HEPES,
KCl, pH = 7.4 HEPES-buffered saline (HBS), with 0.2% (w/v) bovine serum albumin (BSA) for 15 min at 37°C, after which it was kept on ice until use.
Contact system activation assays
Purified FXII exposure to single purified enzymes. ) and absorbance was read at 450 nm. A bFXIIa standard curve was included on each plate, which was plotted in Prism Graphpad 7.0 (Graphpad Software Inc., La Jolla, CA, USA) using a sigmoidal 4PL fit model to which sample concentrations of FXIIa were related.
C1-inhibitor-enzyme complex ELISA
C1INH-enzyme complex ELISAs were performed as previously described [14] . Capture nanobody 1B12 against cleaved C1INH was immobilized at 5 lg mL À1 in HBS on a maxisorp plate overnight at 4°C. ) and absorbance was measured at 405 nm. As a standard curve, a DXS-activated plasma (30 lg mL À1 DXS-500k for 30 min) was included.
Sample concentrations were plotted against the standard curve via Prism Graphpad 7.0 (Graphpad Software Inc.) using a sigmoidal 4PL fit.
Western blotting
Samples from contact system activation assays were diluted 20 times in (non-)reducing sample buffer ( . Blots were extensively washed with TBST, followed by distilled water and analyzed on a near infra-red Odyssey scanner (LI-COR, Leusden, the Netherlands).
In silico predictions
Proline-rich regions of mature FXII amino acid sequences (https://www.uniprot.org; Human, P00748; Mice, Q80YC5; Rat, D3ZTE0; Bovine, P98140; Pig, O97507) were analyzed with Peptide Cutter or Prosper software for the presence of putative cleavage sites with probability scores > 50% [16, 18] .
Statistical analysis
Statistics were performed by one-way ANOVA. P < 0.05 was considered significant. All data analyses were performed with Prism Graphpad 7.0 (Graphpad Software Inc.).
Results
The surface-binding domains of activated factor XII limit its activity in solution Factor XII contains three cleavage sites that are cleavable by PKa (R334, R343 and R353) [19, 20] . Cleavage after R343 and R353 will result in a two-chain molecule (aFXIIa), as a result of an intramolecular disulfide bridge (Cys340-Cys467) in FXII. In contrast, cleavage after R334 will result in a large (50 kDa; sequence I1-R334) fragment that contains the surface-binding domains and small fragment (~28 kDa; bFXIIa; sequence N335-S596) containing the catalytic domain. Mutagenesis of R353 into an alanine (Fig. 1A) prevents FXII activation by PKa, as determined by FXIIa ELISA (R353A; Fig. 1B) . A minor fraction of FXII is truncated by cleavage after R334, as is visible in western blots under non-reducing conditions (Fig. 1C) . Under reducing conditions it becomes clear that PKa predominantly cleaves after R353 in wild-type FXII (FXII-WT; Fig. 1C ). Residual cleavage is seen with FXII-R353A as a result of the two alternative ). Data represent means AE SD of three separate experiments, all performed in duplicate. Data were analyzed by one-way ANOVA (****P < 0.0001).
cleavage possibilities. Cleavage after R353 is essential for the development of enzymatic activity in chromogenic substrate assays (Fig. 1D, Figure S1A ) [19] . In a comparable manner, plasmin generates FXIIa from FXII zymogen, albeit much less efficiently (Fig. 1E) . Some FXII is truncated into similar non-disulfide-linked products ( Fig. 1F ; non-reduced). In contrast to PKa-mediated cleavage, plasmin does not show a preference for FXII-WT over FXII-R353A; both form similar amounts of two-chain products ( Fig. 1F; reduced) . This can be attributed to a plasmin-specific cleavage event at position K346 [21] . Nonetheless, enzymatic activity is critically dependent on R353 cleavage, indicating that K346 cleavage does not independently trigger FXII activation and R353 cleavage is a prerequisite (Fig. 1G, Figure S1A ).
To investigate the importance of FXII truncation at position R334, we generated FXII-R334A ( Fig. 2A) . This mutant generates comparable amounts of FXIIa in response to PKa (Fig. 2B ) and plasmin (Fig. 2E ). As expected, truncation by both enzymes is abrogated ( Fig. 2C,F ; non-reduced; for PKa and plasmin, respectively). Correspondingly, FXII-R334A is less fragmented by PKa when analyzed by SDS-PAGE under reducing conditions ( Fig. 2C; reduced) . As before, fragmentation is similar between FXII-WT and FXII-R334A when exposed to plasmin ( Fig. 2F; reduced) . Remarkably, we observed a~50% lower enzymatic activity in FXII-R334A compared with FXII-WT in chromogenic substrate assays after exposure to either PKa or plasmin (Fig. 2D,G, respectively, Figure S1B ). These experiments suggest that cleavage after R334 accelerates FXII activation or enhances enzyme activity, possibly because the surface binding domains of FXIIa interfere with substrate conversion (Fig. 2H) .
Truncation of pathogenic factor XII mutant T309K primes it for activation in solution
We recently identified that mutations in FXII that cause HAE (FXII-HAE) introduce additional cleavage sites within the proline-rich region of FXII, which are sensitive to plasmin (Fig. 3A, T309K indicated in yellow) . Stimulation of plasmin activity in patient plasma provokes uncontrolled bradykinin production [14] . Motivated by our previous experiments on the role of FXII truncation (Fig. 2) , we investigated the consequences of plasminmediated truncation of this pathogenic mutant in further detail. We therefore exposed FXII-T309K to low levels of plasmin (67 nmol L À1 ). At these concentrations, there is negligible FXIIa formation (Fig. 3B) , despite considerable truncation ( Fig. 3C ; non-reduced). This indicates that plasmin prefers cleavage after residue K309 in the pathological mutant over R353. In a similar manner, we exposed FXII-T309K to low levels of PKa (1.4 nmol L À1 ). At these PKa concentrations, negligible FXIIa formation is observed (Fig. 3B ) and no truncation takes place ( Fig. 3C ; nonreduced). However, plasmin and PKa act synergistically on FXII-T309K: when this mutant is simultaneously exposed to low levels of both enzymes, FXIIa formation is strongly amplified ( Fig. 3B ; prognosed cooperative activity of both enzymes indicated by striped bar). During this reaction, plasmin-truncated FXII is cleaved at position R353 by PKa, yielding a two-chain molecule ( Fig. 3C; reduced) . As a result, FXII-T309K only develops enzyme activity when simultaneously exposed to both enzymes (Fig. 3D, Figure S1C ). This phenomenon is specific to the pathogenic form of FXII. FXII-WT does not form FXIIa in response to the combined presence of low levels of plasmin and PKa (Fig. 3E) , is resistant to truncation by plasmin (Fig. 3F ) and does not develop enzymatic activity (Fig. 3G, Figure S1C ). These findings indicate that site R353, which is critical to FXII activation, is shielded from enzymatic cleavage in solution by the N-terminally positioned surface-binding domains (Fig. 3H) . We next considered the possibility that these observations reflect a physiological phenomenon.
Non-canonical cleavage by neutrophil elastase or cathepsin K primes factor XII for activation in solution
Because of its composition, the unique highly unstructured proline-rich region of FXII may act as a hinge to connect the surface-binding domains of FXII to its catalytic domain. Our previous experiments with FXII-T309K indicated that cleavage sites that are present in this region are accessible for cleavage. We subsequently considered the possibility that naturally occurring cleavage sites are present in this region. For the identification of putative naturally occurring cleavage sites for alternative enzymes in the proline-rich region, we performed an in silico analysis. A selection of the predicted enzymes and their cleavage sites across several species is presented in Table 1 . These predictions show possible cleavage sites for neutrophil elastase (elastase 2) in the proline-rich region (Fig. 4A ). This enzyme is amongst others expressed by neutrophils, basophils and mast cells, which have been previously tied to contact activation [22] . Interestingly, it was previously established that neutrophil elastase cleaves FXII into two fragments of 52 kDa and 28 kDa [23, 24] . This suggests a cleavage site in the vicinity of the proline-rich region. Extended exposure of FXII to elastase destroys its procoagulant and enzymatic activity [25] . This may be mediated through a predicted elastase cleavage site after V354, a single amino acid behind the activating cleavage site R353. We explored this in further detail: when FXII is exposed to neutrophil elastase, elevated levels of FXIIa are detected by ELISA (Fig. 4B ). This is accompanied by FXII truncation, seen under non-reducing conditions (Fig. 4C) . The presence of low, non-activating levels of PKa (1.4 nmol L À1 ) increases FXIIa levels synergistically ( Fig. 4B ; prognosed cooperative activity of both enzymes indicated by the striped bar). Analyses under reducing conditions point out that~50% of FXIIa forms a twochain product in the presence of neutrophil elastase (Fig. 4C) . This cleavage by elastase does not independently activate FXII in a chromogenic substrate assay (Fig. 4D, Figure S1D ), despite recognition of (some of) the cleavage products by ELISA. However, in the presence of low, non-activating levels of PKa (1.4 nmol L À1 ), all truncated FXII is converted into a two-chain molecule, indicated by a migratory shift seen by SDS-PAGE under reducing conditions (Fig. 4C ). This synergistic action strongly promotes enzymatic activity (Fig. 3D) . These experiments indicate that two naturally occurring cleavage sites for neutrophil elastase in FXII are able to control its activation in solution. One of these cleavage sites (at a currently unidentified position) mediates truncation by elastase (Fig. 4H) . This removes the sequence that shields R353, priming FXII for activation by PKa in solution. Cathepsin K is expressed by osteoclasts and monocytes [26] . This cysteine protease mediates the breakdown of collagen and elastin and is implicated in osteoporosis and emphysema. Its expression is upregulated by inflammatory cytokines after tissue injury. Our in silico analyses predict a cleavage site for cathepsin K in the proline-rich region of FXII (Table 1 ; Fig. 4A ). Similar to our findings with elastase, we found that cathepsin K generates products from FXII that are recognized in FXIIa ELISAs (Fig. 4E) . By western blots, we confirmed that cathepsin K cleaves FXII into two fragments ( Fig. 4F ; nonreduced). In the presence of low, non-activating levels of PKa (1.4 nmol L À1 ), FXIIa levels increase synergistically ( Fig. 4E ; prognosed cooperative activity of both enzymes indicated by the striped bar). This corresponds with a migratory shift that is visible by western blotting under reducing conditions, indicating activating cleavage by PKa ( Fig. 4F; reduced) . As a result, FXII only develops enzymatic activity in the combined presence of both enzymes (Fig. 4G, Figure S1E ).
Removal of the shielding sequence by neutrophil elastase primes factor XII for activation in plasma
In a final series of experiments, we reconstituted FXIIdepleted plasma with FXII or FXII that had been preexposed to neutrophil elastase. We determined the plasma levels of complexes between FXIIa or PKa and C1INH as a measure of contact activation in plasma in the presence or absence of low levels of PKa (11.3 nmol L À1 ). We found that the combined actions of neutrophil elastase and PKa led to high levels of FXIIa-C1INH complexes, as well as PKa-C1INH complexes ( Fig. 5A,B ; prognosed cooperative activity of both enzymes indicated by striped bar). Finally, we analyzed the cleavage of high-molecular-weight kininogen (HK) by western blotting. This reflects the liberation of bradykinin from its precursor molecule [27] . Our experiments showed that pre-exposure of FXII to neutrophil elastase (which truncates it) boosts HK cleavage (Fig. 5C ). Densitometric analysis of HK cleavage from repeated experiments at low PKa levels (11.6 nmol L À1 ) shows that cleaved HK levels are~2-fold higher than can be attributed to the cooperative actions of both enzymes ( Fig. 5D ; prognosed cooperative activity of both enzymes indicated by the striped bar).
Discussion
Excessive contact system activation has been linked to a variety of inflammatory conditions [4, [28] [29] [30] . Because the contact system derives its name from surface-dependent enzyme reactions in coagulation assays, it is logical to assume that surfaces are a prerequisite for contact system activation in vivo. We here present evidence for a general biochemical mechanism that controls FXII activation in solution.
1 Cleavage after R334 enhances the enzyme activity of FXIIa. A mutant in which this cleavage site is disabled (R334A) has a strongly reduced enzyme activity after exposure to PKa or plasmin (Fig. 2) . Our findings suggest that the surface-binding domains of FXIIa shield its active site. 2 Truncation of the pathological mutant FXII-T309K by plasmin primes it for activation by PKa in solution (Fig. 3) . These experiments suggest that the activating cleavage site after R353 is shielded from cleavage. These findings indicate a two-step mechanism in which FXII-T309K is first truncated, exposing R353 for subsequent cleavage by PKa, as we previously proposed [15] . 3 The proline-rich region of FXII contains naturally occurring cleavage sites for a variety of enzymes, including neutrophil elastase and cathepsin K. These enzymes are unable to directly activate FXII. However, truncation by these enzymes primes FXII for activating cleavage by PKa (Figs 4 and 5 ). These findings are strikingly similar to our previous observations with FXII-T309K. However, in this case no pathological mutation is required.
In earlier studies, it was demonstrated that the binding of FXII to the polyanion dextran sulfate [31] , or the binding of monoclonal antibodies to the surface binding domains, lowers the threshold for FXII activation by PKa [9, 10] . This suggests that the activating cleavage site R353 is shielded, unless FXII binds to activating surfaces.
In the current study, we explore the proline-rich region for the presence of truncating cleavage sites. The prolinerich region is of particular interest given its unique presence in FXII. The sequence from the proline-rich region up to Cys 340 is not strictly conserved between species. However, prediction models indicate that cleavage sites for neutrophil elastase, matrix metalloprotease 9 (MMP-9) and cathepsin K are generally present within these sequences across species (Table 1) . Truncations with similar functionality have been shown to take place outside the proline-rich region: previous studies identified a cleavage site for MMP-12 and MMP-14 after S331 [32] . These studies concluded that this cleavage event degrades FXII, impairing its ability to contribute to coagulation and fibrinolysis. Our current findings suggest otherwise: although elimination of its surface-binding domains should reduce its capacity as a clotting factor, its potential to become activated in solution should increase. Our data suggest that neutrophil elastase is not only a negative regulator of FXII [25] : truncation strongly accelerates FXII activation in solution (Fig. 4) . The localized swelling that is generally seen in HAE suggests that bradykinin production is a local process [33] . However, simultaneous swelling at multiple locations occurs in some patients, which suggests a systemic activation process [34] .
Despite intensive investigation, a contact surface has not been pinpointed in bradykinin-driven disease. We generally assume that physiological contact activation requires a surface, which may be delivered by platelets during clot formation [35] . By analogy, we proposed that bradykinin production on vascular endothelium is a cell surface-receptor-dependent mechanism [36] . These mechanisms depend on the surface-binding domains of FXII and (c)HK. When FXII is fragmented by PKa, bFXIIa can continue its role as a PK activator (but not as a clotting factor) in a surface-independent manner [7] . Our findings in FXII-HAE suggest that accelerated FXII fragmentation and unregulated PK activation by dissociated bFXIIa form the molecular basis for swelling attacks [14] . Our current findings expand on this principle: we propose that bradykinin production can also be initiated in the absence of a surface when FXII is truncated by enzymes that are not classically linked to the contact system. Future studies are needed to explore whether non-canonical truncation of FXII contributes to the role of the contact system in pathology. This may, for example, be the case in anaphylaxis, where FXII is cleaved in a PK-independent manner [3] . Our studies identify that truncation of FXII primes the molecule for activation in solution. We hypothesize that the proline-rich region acts as a versatile sensor: it can be cleaved by a variety of enzymes that are released by or activated by (inflammatory) cells. This cleavage removes the sequence that shields R353, accelerating FXII activation and, ultimately, bradykinin production. 
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